These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19557593

  • 21. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G.
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
    [Abstract] [Full Text] [Related]

  • 22. High serum concentration of total inhibin in polycystic ovary syndrome.
    Tsigkou A, Luisi S, De Leo V, Patton L, Gambineri A, Reis FM, Pasquali R, Petraglia F.
    Fertil Steril; 2008 Nov; 90(5):1859-63. PubMed ID: 18423626
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome.
    Noyan V, Yucel A, Sagsoz N.
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug 10; 115(2):200-5. PubMed ID: 15262356
    [Abstract] [Full Text] [Related]

  • 25. Serum insulin patterns and the relationship between insulin sensitivity and glycaemic profile in women with polycystic ovary syndrome.
    Seneviratne HR, Lankeshwara D, Wijeratne S, Somasunderam N, Athukorale D.
    BJOG; 2009 Dec 10; 116(13):1722-8. PubMed ID: 19775306
    [Abstract] [Full Text] [Related]

  • 26. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct 10; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D, Rousso D, Koliakos G, Kourtis A, Katsikis I, Farmakiotis D, Votsi E, Diamanti-Kandarakis E.
    Fertil Steril; 2006 Jun 10; 85(6):1778-83. PubMed ID: 16650418
    [Abstract] [Full Text] [Related]

  • 30. [Comparison of HOMA IR with the minimal model for measuring insulin sensitivity in polycystic ovary syndrome].
    Amador N, Espinoza G, Guízar JM, González M, Alpízar M.
    Rev Invest Clin; 2001 Jun 10; 53(5):407-12. PubMed ID: 11795106
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 10; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Macut D, Panidis D.
    Hum Reprod; 2013 Mar 10; 28(3):785-93. PubMed ID: 23315058
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
    Markantes G, Saltamavros AD, Vervita V, Armeni AK, Karela A, Adonakis G, Decavalas G, Georgopoulos NA.
    Gynecol Endocrinol; 2011 Dec 10; 27(12):971-7. PubMed ID: 21501001
    [Abstract] [Full Text] [Related]

  • 38. Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome.
    El-Mesallamy HO, Abd El-Razek RS, El-Refaie TA.
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun 10; 168(2):178-82. PubMed ID: 23434327
    [Abstract] [Full Text] [Related]

  • 39. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome.
    Cakal E, Ustun Y, Engin-Ustun Y, Ozkaya M, Kilinç M.
    Gynecol Endocrinol; 2011 Jul 10; 27(7):491-5. PubMed ID: 20626239
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.